Get started
Author

Darryl P. Toth

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
2015 · Mark Lebwohl, Bruce Strober, et al. · New England Journal of Medicine · 845
PDF
A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
2003 · Mark Lebwohl, Stephen K. Tyring, et al. · New England Journal of Medicine · 568
PDF
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
2006 · Kenneth B. Gordon, Richard G. Langley, et al. · Journal of the American Academy of Dermatology · 509
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies
2021 · Kim Papp, Jacek C. Szepietowski, et al. · Journal of the American Academy of Dermatology · 324
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
2015 · Ulrich Mrowietz, Craig L. Leonardi, et al. · Journal of the American Academy of Dermatology · 208
Relapse, rebound, and psoriasis adverse events: An advisory group report
2006 · Wayne Carey, Scott Glazer, et al. · Journal of the American Academy of Dermatology · 148
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies
2022 · Kim Papp, Jacek C. Szepietowski, et al. · Journal of the American Academy of Dermatology · 105
Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population
2010 · Kim A. Papp, Yves Poulin, et al. · Journal of the American Academy of Dermatology · 102
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
2022 · Andrew Blauvelt, Richard G. Langley, et al. · Journal of the American Academy of Dermatology · 83
Skin and Diabetes
1996 · R. Gary Sibbald, Sandra J. Landolt, et al. · Endocrinology and Metabolism Clinics of North America · 72
A Review of Malignancies Observed during Efalizumab (Raptiva®) Clinical Trials for Plaque Psoriasis
2006 · Craig L. Leonardi, Darryl Toth, et al. · Dermatology · 59
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents
2025 · Robert Bissonnette, Jennifer Soung, et al. · New England Journal of Medicine · 45
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis
2023 · Matthew J. Zirwas, Zoe D. Draelos, et al. · JAMA Dermatology · 42
PDF
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open‐label, multicenter, Phase IIIb study
2007 · Alan Menter, Tiffani K. Hamilton, et al. · International Journal of Dermatology · 32
Safety profile of intravenous and subcutaneous siplizumab, an anti‐CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double‐blind, placebo‐controlled studies
2010 · Richard G. Langley, Kim Papp, et al. · International Journal of Dermatology · 27
Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents
2025 · Yan Zhao, Melinda Gooderham, et al. · JAMA Dermatology · 26
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial
2024 · Linda Stein Gold, David N. Adam, et al. · Journal of the American Academy of Dermatology · 21
Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies
2020 · Kim Papp, Jacek C. Szepietowski, et al. · SKIN The Journal of Cutaneous Medicine · 18
PDF
A fixed-dose combination of adapalene 0.1%–BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne
2011 · Robert T. Brodell, Bethanee J. Schlosser, et al. · Journal of Dermatological Treatment · 18
Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab
2009 · Robert Bissonnette, Richard G. Langley, et al. · Archives of Dermatological Research · 16
Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study
2011 · Rod KUNYNETZ, Wayne CAREY, et al. · European Journal of Dermatology · 13
Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence
2006 · Kim A Papp, Darryl Toth, et al. · BMC Dermatology · 13
PDF
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial
2022 · Linda Stein Gold, Javier Alonso-Llamazares, et al. · American Journal of Clinical Dermatology · 12
PDF
Long-term efficacy of up to 15 months’ efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis
2008 · Darryl P. Toth, Kim Papp, et al. · Dermatologic Therapy · 6
PDF
27874 Correlation of itch response to roflumilast cream with disease severity and patient-reported outcomes in patients with chronic plaque psoriasis
2021 · Linda Stein Gold, Javier Alonso-Llamazares, et al. · Journal of the American Academy of Dermatology · 5
Works count: 44
Citation count: 3,345
H-index: 18
I10-index: 23
Year
Topic
Type